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Development 
of antisense‑mediated myostatin 
knockdown for the treatment 
of insulin resistance
Wouter Eilers1*, Mark Cleasby2 & Keith Foster1
Myostatin is a negative regulator of muscle mass and its inhibition represents a promising strategy 
for the treatment of muscle disorders and type 2 diabetes. However, there is currently no clinically 
effective myostatin inhibitor, and therefore novel methods are required. We evaluated the use 
of antisense phosphorodiamidate morpholino oligomers (PMO) to reduce myostatin expression 
in skeletal muscle and measured their effects on muscle mass and glucose uptake. C57/Bl6 mice 
received intramuscular or intravenous injections of anti‑myostatin PMOs. Repeated intramuscular 
administration lead to a reduction in myostatin transcript levels (~ 20–40%), and an increase in muscle 
mass in chow and high‑fat diet (HFD)‑fed mice, but insulin‑stimulated glucose uptake was reduced 
in PMO‑treated muscles of HFD‑fed mice. Five weekly intravenous administrations of 100 nmol 
PMO did not reduce myostatin expression, and therefore had no significant physiological effects. 
Unexpectedly, exon skipping levels were higher after intramuscular administration of PMO in HFD‑ 
than chow‑fed mice. These results suggest that a modest PMO‑induced reduction in myostatin 
transcript levels is sufficient to induce an increase in muscle mass, but that a greater degree of 
inhibition may be required to improve muscle glucose uptake.
Modulation of the expression of specific genes using antisense oligonucleotides (AOs) is a potential therapeutic 
strategy for diseases of both genetic and non-genetic origins. Hybridisation of AOs to specific complementary 
sequences on the (pre-)mRNA allows the recruitment of RNAse, which induces degradation of the target tran-
script or the steric blockade of RNA regulatory proteins, to alter RNA processing. Examples of how this could 
modify disease phenotypes include the manipulation of specific signalling pathways or the correction of aber-
rant RNA splicing caused by genetic mutations. In recent years, ten AO-based therapies have received market 
approval, nine of which are currently marketed. However, most of these therapies target transcripts in the liver, 
because this is the primary site of AO accumulation after systemic  administration1. Targeting of other tissues and 
transcripts has necessitated local delivery; for example, intrathecal administration to target the central nervous 
 system2 or intra-orbital administration for retinal  disorders3. The major exception to this is the use of AOs for 
Duchenne muscular dystrophy (DMD), the aim of which is to target the dystrophin transcript in skeletal and 
cardiac muscle cells to restore expression of a truncated version of the dystrophin protein by modifying the pre-
mRNA splicing  pattern4. The development of AO-based therapies able to target genes in a body-wide fashion is 
of great potential importance for the treatment of non-genetic diseases, because of the relative ease with which 
an antisense sequence specific to an RNA target of interest can be designed. Skeletal muscle is a good exam-
ple of a tissue which could be targeted by effective systemic AO-based therapies, given its importance for the 
maintenance of mobility during aging, the lack of therapies available to counteract muscle wasting conditions, 
including sarcopenia and cancer cachexia, and its importance for normal metabolism, by virtue of its role as a 
major store of protein and glucose.
Insulin resistance (IR) is an essential pre-requisite for the development of type 2 diabetes (T2D), a disease 
which is reaching pandemic status and represents a huge healthcare  challenge5. IR in skeletal muscle is of par-
ticular significance, because this tissue accounts for the majority of post-prandial glucose disposal. IR commonly 
develops secondary to, or in association with obesity, the prevalence of which is rapidly increasing worldwide. 
Whereas resistance exercise can ameliorate IR, in addition to counteracting  sarcopenia6, compliance requires 
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supervised interventions, for which there are insufficient healthcare resources. Thus, effective therapies are 
required to reverse sarcopenia or to maximise the impact of activity, in order to maintain muscle mass.
Myostatin/growth-differentiation factor-8 (MSTN) is a member of the transforming growth factor (TGF)
β superfamily that is synthesised in and secreted from skeletal muscle, where it has inhibitory effects on dif-
ferentiation and growth, as demonstrated by the pronounced effects of gene-inactivating mutations in multiple 
 species7–11. Conversely, greater expression of MSTN is a key feature of  cachexia12–14 and  sarcopenia15,16. We and 
others have demonstrated that postnatal inactivation of MSTN results in hypertrophy, and a consequent increase 
in muscle mass and strength, along with an increase in insulin  sensitivity17,18. MSTN also seems to have a selec-
tive effect upon  adipogenesis19,20 and genetic or pharmacological inactivation of MSTN increases lipolysis and 
fatty acid oxidation in peripheral  tissues21. Thus, therapeutic MSTN silencing has the potential to ameliorate IR 
via dual mechanisms: an augmentation of muscle mass and a reduction in adipose mass.
Attempts at inhibiting MSTN action by targeting its receptor (ActRIIB) showed some therapeutic  potential22. 
However, recent clinical trials using a soluble ActRIIB decoy in healthy and dystrophic individuals were associ-
ated with unacceptable adverse events (http://clini caltr ials.gov/ct2/show/NCT01 09976 1), likely due in part to a 
lack of specificity, because many other TGFβ family members signal through ActRIIB. Furthermore, while clinical 
trials using anti-myostatin antibodies or adnectins to inhibit myostatin in a variety of disease contexts have shown 
small increases in lean body  mass23, they often fail to demonstrate improvements in muscle  function24 leading 
to a halt in their development. Therefore, alternative specific approaches to MSTN inhibition are required. Of 
these, AO-induced exon skipping, aiming to disrupt the reading frame of the MSTN transcript, is particularly 
promising. Phosphorodiamidate morpholino oligomers (PMO) have received FDA approval for  DMD25–27. The 
PMO chemistry of AO has excellent safety and toxicological profiles and is stable, making it suitable for clinical 
use. Furthermore, we have previously demonstrated that reducing MSTN gene expression by peptide-conjugated 
PMO-induced exon skipping induces muscle hypertrophy in  mice28.
In this study, we aimed to evaluate myostatin exon skipping using antisense PMOs as a potential therapeutic 
strategy by determining its effects on muscle mass and whole-body and skeletal muscle insulin sensitivity in mice.
Results
PMO‑induced myostatin exon skipping in skeletal muscle. We evaluated a number of PMOs com-
plementary to exon 2 or overlapping the splice donor site of intron 2 of the mouse myostatin transcript, on the 
basis of the location of binding sites for serine/arginine-rich splicing factors predicted using ESEfinder v3.029,30 
by administering a single local injection into the cranial compartment of the lower leg, which includes the TA 
and EDL muscles, followed by RT-PCR analysis of myostatin exon 2 skipping 1 week post-injection. We found 
that a mixture of two PMO 30-mers (Fig. 1a) resulted in the highest level of exon skipping in the TA muscle 
when compared to single PMOs at an equimolar total PMO concentration (data not shown). Exon skipping was 
verified by gel electrophoresis and DNA sequencing (Fig. 1b,c). However, a single injection was insufficient to 
significantly reduce the expression of full-length myostatin transcript in the TA muscle (Fig. 1d).
Figure 1.  Exon skipping induced by anti-myostatin PMOs. (a) Schematic representation of the mouse 
myostatin transcript, showing exons (boxes) and introns (lines), and indicating the approximate location of 
the target sequences of the two PMOs used (a,b, black bars) and the primer pairs used to amplify an exon 1 
fragment (grey arrows labelled e1), an exon 1–2 fragment (grey arrows labelled e1e2), or an exon 1–3 fragment 
(black arrows) by RT-PCR. (b) C57Bl/6 mice (n = 5 per PMO) received an intramuscular injection of 5 nmol of 
anti-myostatin and 1 week later exon skipping was evaluated by RT-PCR. The unskipped transcript amplifies 
as a 500 bp product and the skipped transcript as a 126 bp product. “H2O” indicates the non-template control. 
Black arrows indicate the expected position of the unskipped (exon 1–2–3) and skipped (exon 1–3) transcript 
amplicons. (c) Result of Sanger sequencing of the 126-bp PCR product obtained from PMO-treated muscle. The 
sequence corresponding to the 3′ end of exon 1 and the 5′ end of exon 3 is indicated. (d) Unskipped myostatin 
transcript expression following a single intramuscular administration of PMO. Data are shown as individual 
data points, with data from the same animals connected by lines.
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Repeated intramuscular administration of anti‑myostatin PMO increases muscle mass. To 
determine whether repeated PMO administration reduces full-length myostatin transcript expression, we per-
formed four weekly intramuscular TA injections of anti-myostatin or scrambled PMOs to 5-month-old chow-
fed C57Bl/6 mice (‘Experiment 1’ in the Methods section). Full-length myostatin transcript expression in the TA 
muscles was 38% lower (p < 0.001) in the myostatin PMO-treated muscles (Fig. 2a), although there was a 13% 
increase (p < 0.01) in the total myostatin transcript expression (Fig. 2b). The TA and EDL masses in the myosta-
tin PMO-treated leg were significantly higher (+ 3.5 and + 4.2%, respectively; p < 0.05; Fig.  2c,d). These data 
demonstrate that the effect of the anti-myostatin PMOs increased during the course of the experiment and that 
muscle mass can be increased by myostatin exon skipping, even if only a reduction in, rather than a complete 
elimination of, full-length myostatin transcript was achieved.
High‑fat diet feeding increases the level of PMO‑induced exon skipping. Next, we evaluated 
the effect of repeated intramuscular myostatin PMO administration on exon skipping levels, muscle mass and 
insulin sensitivity in chow- and HFD-fed mice (‘Experiment 2’ in the Methods section). The HFD-fed mice had 
higher body mass (+ 18%, p < 0.001, Fig. 3a) and epididymal fat pad mass (+ 238%, p < 0.001, Fig. 3b) than the 
chow-fed mice, as well as higher resting blood glucose concentrations (+ 17%, p < 0.05, Fig. 3c) and lower insulin 
sensitivity (Fig. 3d). Exon skipping was induced in all of the PMO-treated muscles in both diet groups (Fig. 3e). 
Unexpectedly, exon skipping levels in the HFD-fed mice were significantly higher than in the chow-fed mice 
(HFD: 42%, Chow: 22%, p < 0.05, Fig. 3f). This led to a greater reduction in full-length myostatin transcript in 
the HFD-fed mice (HFD: − 41%, Chow: − 23%, Fig. 3g). However, there was no difference in the expression of 
full-length myostatin mRNA between saline and PMO-injected muscles (Fig. 3h). Finally, the total myostatin 
mRNA expression tended to be lower in HFD-fed mice (p = 0.06; Fig. 3h).
Anti‑myostatin PMO increases muscle mass but not insulin sensitivity in chow‑ and HFD‑fed 
mice. TA muscle mass was significantly higher in the myostatin PMO-treated muscles of both chow- and 
HFD-fed mice (+ 6.6%, p < 0.01 and + 6.5%, p < 0.01, Fig. 4a). Thus, despite the difference in the reduction in full-
length myostatin mRNA achieved between chow- and HFD-fed mice, the increase in mass of the PMO-treated 
TA muscle was the same in each diet group. However, EDL muscle mass was significantly increased only in the 
chow-fed mice (+ 4.7%, p < 0.05, Fig. 4b). Unexpectedly, we found a significant reduction in glucose uptake into 
Figure 2.  Four weeks of weekly PMO injections reduce full-length myostatin transcript and increase muscle 
mass. (a) Relative full-length myostatin transcript (e1e2 fragment) expression in muscles treated with anti-
myostatin (Mstn) or scrambled (Scr.) PMO. (b) Relative total myostatin transcript (e1 fragment) expression in 
muscles treated with anti-myostatin (Mstn) or scrambled (Scr.) PMO. C&D: TA (c) and EDL (d) muscle masses 
after treatment with Mstn or Scr. PMO. Data are shown as individual data points, with data from the same 
animals connected by lines. Bars indicate the mean value for each group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. Scr. 
PMO. N = 8 per group.
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Figure 3.  Higher levels of myostatin exon skipping in the muscles of high-fat diet-fed than chow-fed mice 
after repeated PMO injection. (a–d) Body mass (a); Epididymal fat pad mass (b); Absolute blood glucose 
concentrations during IPITT (c); and Relative blood glucose concentrations during IPITT (d) of chow- and 
high fat diet (HFD)-fed mice. (e) RT-PCR/agarose gel analysis of myostatin exon skipping. Ex1/2/3: Unskipped 
myostatin transcript; Ex1/3: Skipped myostatin transcript; NT: non-template control; Sal: Saline-treated muscle. 
The two gel images shown are unmodified parts of the same original gel image. (f) Calculated percentage exon 
skipping of the myostatin transcript in chow- and HFD-fed mice. (g,h): Unskipped (g) and total (h) myostatin 
transcript expression after repeated PMO administration. Data are shown as individual data points and 
means ± S.D. (a,b,f), as means ± S.E.M. (c,d) or as individual data points with bars indicating the mean values 
and data points from the same animals connected by lines (g,h). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. 
N = 10 per group.
Figure 4.  Myostatin exon skipping after repeated PMO injections increases muscle mass, but not insulin 
sensitivity, in high-fat diet-fed mice. (a,b) Muscle mass of TA (a) and EDL (b) muscles from chow- and HFD-fed 
mice after repeated i/m PMO or saline administration. (c) Glucose uptake into TA muscle per unit muscle mass 
during the IPITT. (d) GLUT4 transcript levels in TA muscle. Data are shown as individual data points with bars 
indicating the mean values and data points from the same animals connected by lines. *p < 0.05, **p < 0.01 vs. 
Saline within same diet group. +++p < 0.001 vs. saline in the other diet group. N = 10 per group.
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the PMO-treated TA muscles of HFD-fed mice during an IPITT (− 22.6%, p < 0.05, Fig. 4c). Transcript levels of 
Slc2a4, which encodes the glucose transporter GLUT4, were lower in saline-injected TA muscles of HFD-fed 
mice than in the muscles of chow-fed mice (− 27%, p < 0.001), but did not differ between PMO-treated and saline 
control muscles (Fig. 4d).
Repeated intravenous administration of anti‑myostatin PMOs does not reduce myostatin 
expression sufficiently to increase muscle mass or improve insulin sensitivity. To test the fea-
sibility and effects of the systemic delivery of anti-myostatin PMOs in HFD-fed mice, we performed repeated 
intravenous PMO administrations for 5 weeks (‘Experiment 3′ in the Methods section). The body mass of the 
HFD-fed mice was higher than that of the chow-fed mice, but was similar in the PMO- and saline-injected HFD-
fed mice (Fig. 5a). The relative increase in body mass after the start of the injections was less in the PMO-treated 
HFD-fed mice than in the saline-treated HFD-fed mice (total increase: 15% vs. 21%, respectively; p < 0.05; 
Fig. 5b). However, there was no effect of PMO administration on blood glucose or insulin sensitivity during 
an IPITT (Fig. 5c,d). In addition, we found no difference in fat pad mass or the mass of three different muscles 
between PMO- and saline-treated HFD-fed mice (Fig. 5e–h). When we analysed myostatin exon skipping in the 
TA and soleus muscles, we detected only very low expression of the skipped myostatin transcript (Fig. 5i) in the 
muscles of the PMO-treated mice. Consistent with this, we detected no significant differences in unskipped and 
total myostatin transcript expression in the TA and soleus muscles by real-time PCR (Fig. 6a,b).
Systemic myostatin inhibition could affect other tissues that express myostatin, such as adipose tissue. In addi-
tion, it has been suggested that myostatin is expressed in the  liver31. We therefore analysed myostatin expression 
and exon skipping in the inguinal and epididymal fat pads and in the liver. Myostatin expression was detected in 
Figure 5.  Intravenous administration of unmodified PMOs does not induce sufficient exon skipping to increase 
muscle mass or decrease fat mass in high-fat diet-fed mice. (a,b) Body mass (a) and percentage increase in body 
mass (b) measured weekly after the start of i/v PMO or saline administration (start: week 8). (c,d) Absolute 
(c) and relative (d) blood glucose concentrations during the IPITT. E–H: Epididymal fat pad (e), TA muscle 
(f), SOL muscle (g) and Gastrocnemius (h) muscle masses in saline-treated chow-fed (Chow-S), saline-
treated HFD-fed mice (HFD-S) and PMO-treated HFD-fed mice (HFD-P). (i) RT-PCR/agarose gel analysis of 
myostatin exon skipping in muscle, adipose and liver tissue. Epi: epididymal fat pad. Ing: inguinal fat pad. Liv: 
Liver; NT: non-template control. Ex1/2/3: Unskipped myostatin transcript; Ex1/3: Skipped myostatin transcript. 
Small white arrow indicates PCR product from skipped myostatin mRNA. Data are shown as mean ± S.E.M 
(a–d), with different letters indicating significant differences between the groups at each time point (p < 0.05), or 
as individual data points and means ± S.D. (E–H). N = 10 per group.
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the epididymal adipose tissue from all the mice, but very low levels of skipped myostatin transcript were present 
in adipose tissue from only two PMO-treated HFD-fed mice (Fig. 5i). Myostatin transcript was only detected 
in a subset of the inguinal fat pads and myostatin exon skipping was not detected (Fig. 5i). Finally, myostatin 
expression was not detected in livers of chow-fed or HFD-fed mice (Fig. 5i) and exon skipping was therefore 
not examined.
Discussion
We have evaluated the use of anti-myostatin PMOs to increase muscle mass and improve insulin sensitivity by 
reducing myostatin expression through the induction of exon skipping of the myostatin transcript. Repeated 
intramuscular PMO administration lead to a significant reduction in myostatin transcript level and an increase 
in muscle mass, but no increase in muscle insulin sensitivity in insulin-resistant mice. However, systemic admin-
istration of these PMOs did not reduce myostatin expression. Interestingly, a period of high-fat diet feeding 
increased the level of exon skipping in skeletal muscle.
Local anti-myostatin PMO administration inhibits myostatin signalling by disrupting the expression of 
myostatin in cells successfully targeted by the PMOs, thereby preventing its autocrine/paracrine action. Thus, 
there was no inhibition of myostatin expression or release by cells which did not take up PMOs, nor were the 
effects of myostatin derived from the circulation inhibited. However, our results show that a local reduction in 
full-length myostatin transcript levels of < 100%, which is therefore presumably reflected in a reduction of the 
amount of myostatin protein, rather than elimination of its expression, nonetheless resulted in a significant 
increase in muscle mass (Figs. 2 and 3), suggesting that complete inhibition of myostatin is not required for 
this effect.
Although anti-myostatin PMOs reduced myostatin expression and increased muscle mass, we did not show 
an increase in muscle insulin sensitivity in chow-fed mice, and instead found a reduction in insulin sensitivity 
in HFD-fed mice (Fig. 4). We have previously observed that local myostatin inhibition by adeno-associated 
virus-mediated overexpression of the inhibitory myostatin propeptide induces an increase in muscle insulin 
sensitivity in mice on the same HFD feeding protocol as that used in the current  study32. This was associated 
with a significantly greater increase in muscle mass (~ 23%) than that achieved following the intramuscular 
PMO injections (~ 6.5%, Fig. 4), This suggests that although the degree of myostatin inhibition achieved with 
the local PMO injections was sufficient to increase muscle mass, it was not sufficient to increase muscle insulin 
sensitivity. Local overexpression of the myostatin propeptide in rats resulted in greater glucose uptake which was 
associated with a modest (~ 9%) increase in muscle  mass17. This suggests that large increases in muscle mass are 
not always necessary to increase muscle glucose uptake. Whether the positive effects of myostatin propeptide 
overexpression on muscle glucose uptake are due to more efficient inhibition of locally-produced myostatin, the 
additional effect of blocking myostatin derived from the circulation, or both, is unclear. Myostatin expression 
and secretion from muscle has been reported to be higher in obese  women33. However, in our HFD-fed mice 
myostatin expression in muscle was not higher (Fig. 3h) and therefore, the effects of neither the anti-myostatin 
PMO, nor the myostatin propeptide, can be ascribed to the counteraction of an obesity-associated increase in 
myostatin expression.
Unexpectedly, the level of myostatin exon skipping and myostatin knockdown was higher in HFD-fed than 
chow-fed mice (Fig. 3). It has been previously reported that the incubation of cells with various lipids for sev-
eral hours increases the activity of AOs with a phosphorothioate backbone by increasing AO leakage from late 
 endosomes34. Therefore, it is possible that a similar increase in endosomal leakage of PMOs occurred in the HFD-
fed mice. This raises the question of whether increasing dietary lipid content could help increase the efficacy of 
AOs in clinical studies. Potential corroborating evidence comes from a recent phase I clinical trial for DMD in 
which a PMO AO targeting exon 53 of the dystrophin gene resulted in substantially higher levels of exon skipping 
in one patient who had an unusually high body mass, and was described as having a high body fat  fraction35. 
However, due to the fact that PMO dose was calculated on the basis of body mass, this patient was administered 
Figure 6.  Intravenous administration of unmodified PMOs does not induce sufficient exon skipping to reduce 
the amount of full-length myostatin transcript. (a,b) Expression of full-length (a) and total (b) myostatin 
transcript in TA and SOL muscle of HFD-fed mice treated with anti-myostatin PMO or saline. Data are shown 
as individual data points and means ± S.D. N = 10 per group.
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a larger absolute dose of PMO and had higher serum concentrations of PMO than the other patients in the trial, 
and therefore it is unclear whether their high body fat content contributed to the level of exon skipping observed.
Despite the apparent increase in PMO efficacy in the HFD-fed mice, there was no difference in the increase 
in muscle mass achieved in the saline-injected control muscle between chow-fed and HFD-fed mice (Fig. 4). It 
is possible that, despite the difference in the reduction of myostatin mRNA levels, the reduction in myostatin 
protein levels was not different between the two groups.
While local intramuscular administration of the PMOs led to a significant reduction in full-length myostatin 
transcript levels, our protocol of intravenous PMO administration did not (Fig. 6). The PMO backbone is neu-
trally charged and displays low protein binding compared to antisense oligonucleotide chemistries with ionic 
 backbones36. This results in a good safety profile, but also leads to relatively rapid clearance from the circulation 
by the kidneys which likely compromises its tissue uptake. We previously observed an increase in muscle mass 
in mice after systemic administration of a octa-guanidine dendrimer-PMO  conjugate28. However, although the 
positively charged dendrimer increases exon skipping, it also has significant adverse effects that prevent its trans-
lation to the clinic. Systemic PMO treatment of mdx mice, a model of Duchenne muscular dystrophy, has been 
shown to induce transcript modification in skeletal muscles body-wide37. However, the mechanism of uptake 
of the PMOs into muscle cells is likely to be different in these dystrophic mice compared to wild-type  mice38. 
Likewise, systemic PMO treatment has been shown to induce transcript modification in the skeletal muscles of 
a mouse model of spinal muscular  atrophy39, but these mice are typically treated at the neonatal stage, rather 
than at adult age. Intraperitoneal administration of PMO in a transgenic mouse model expressing a GFP reporter 
gene containing an artificial intron resulted in low levels of transcript modification and GFP  expression40, sug-
gesting that skeletal muscle is not efficiently targeted by systemically administered PMOs. However, it is difficult 
to compare antisense oligonucleotide efficacy between studies, even when the same oligonucleotide chemistry is 
used, because of differences in oligonucleotide length, sequence and target transcript. Nonetheless, we detected 
low levels of exon skipping in skeletal muscle, as well as in epididymal fat deposits, which suggests that increas-
ing the treatment duration, frequency and dose, or improving the AO delivery method, might lead to effective 
gene silencing. Body mass increased less rapidly in the PMO-treated than in the saline-treated HFD-fed mice 
(Fig. 5), but is unclear whether this might be due to myostatin knockdown in a tissue not analysed in this study 
or a non-specific effect based on the PMO chemistry per se. There may have been an effect on myostatin expres-
sion in brown fat, which has been suggested to regulate systemic insulin  sensitivity41, but we did not analyse this 
tissue in the present study.
We conclude that while it is feasible to increase muscle mass by moderately reducing myostatin transcript 
levels using PMO AOs, it is unclear what degree of knockdown is required to improve insulin sensitivity. For 
body-wide effects on muscle mass and insulin sensitivity to occur, larger PMO doses may be required. Future 
efforts should also focus on ways to improve the efficacy of cellular AO uptake. The observation that a HFD 
increased exon skipping levels in muscle could inform these efforts. In addition, modifications to the AOs, such 
as conjugation of peptides or lipids, may enable more efficient cell delivery and intracellular trafficking of AOs, 
thereby improving their efficacy.
Methods
Phosphorodiamidate morpholino oligomer. PMO 30-mers were designed to induce skipping of exon 
2 of the murine myostatin transcript by sterically blocking the binding of essential splicing factors. This results 
in a reading frame shift that prevents translation. A control PMO 30-mer (SCR) that does not have any predicted 
targets in a BLAST search, or saline, were used as controls. PMOs were synthesised by Genetools (Oregon, USA).
An equimolar mixture of two oligos targeting different regions of the myostatin pre-mRNA was used for 
these experiments (PMO A: 5′-TCT TGA CGG GTC TGA GAT ATA TCC ACA GTT -3′; PMO B: 5′-TTT TCA GTT 
ATC ACT TAC CAG CCC ATC TTC -3′; SCR: 5′-GAC GGT TCG GCG ATA ATC CTT CCG CGT CTC -3′).
Animals. Male C57BL/6 mice (Envigo) were housed in animal facilities at the Royal Veterinary College 
(RVC) or the University of Reading (UoR) under a 12:12 h day-night cycle, with standard chow or a high fat 
diet and water available ad libitum. High-fat diet (HFD) was obtained from Research Diets (New Brunswick, 
USA; #D12451), which contained 45% energy derived from fat, 35% from carbohydrates and 20% from protein. 
All experimental procedures were approved by the Animal Welfare Ethical Review Body at the RVC or the 
UoR and conducted under a United Kingdom Home Office licence in compliance with the Animals (Scientific 
Procedures) Act 1986. All experimental procedures were performed in accordance with relevant guidelines and 
regulations.
For intramuscular administration of PMO, mice were anaesthetised with isoflurane (4% induction, 2% main-
tenance) and the cranial aspect of their lower limbs was shaved. PMO was injected into the cranial compartment 
of the left lower leg via a 29G needle, while the right leg was injected with an equimolar amount of SCR PMO 
or saline.
For intravenous (i/v) administration of PMOs, conscious mice were restrained and PMO or saline were 
injected into a lateral tail vein.
Intraperitoneal insulin and glucose tolerance testing. For intraperitoneal insulin tolerance testing 
(IPITT), mice were fasted for 3–4 h before the administration of insulin. Insulin was prepared at 100 iu/ml in 
normal saline and used to resuspend nitrogen-dried 2-[1,2-3H(N)]-deoxy-D-glucose (0.37 MBq). Basal blood 
glucose was measured in tail blood using an Accu-Check Advantage meter (Roche Diagnostics, Burgess Hill, 
West Sussex, UK). A further 10 µl of blood was collected in a microfuge tube containing 1 iu heparin in saline, 
mixed and placed on ice. Immediately afterwards, insulin and deoxyglucose tracer was administered intraperito-
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neally at a dose of 0.75 iu/kg. At 15, 30, 60 and 90 min after insulin administration, blood glucose was measured, 
as described above. After taking the final blood sample, the mice were euthanised by cervical dislocation and 
tissues were dissected, weighed and frozen in liquid nitrogen-cooled isopentane. Glucose clearance into TA 
muscles was determined as described  previously42.
In vivo study design for experiments involving repeated PMO administration. Experiment 1: 
Five-month-old chow-fed male C57BL/6 mice were administered 5 nmol dual anti-myostatin PMO in 50 µl 
saline weekly for 4 weeks into the anterior compartment of a lower leg, as described above. The contralateral 
muscles were injected with SCR PMO. One week after the final injection, the mice were euthanised and their 
tibialis anterior (TA) and extensor digitorum longus (EDL) muscles harvested.
Experiment 2: C57BL/6 mice were switched from regular chow to an HFD at 8 weeks of age, while controls 
continued to consume a normal chow diet for a further 13 weeks. After 8 weeks of these diets, the mice were 
administered weekly intramuscular myostatin PMO injections (5 nmol per injection) into one limb and saline 
injections into the contralateral limb for 4 weeks. IPITTs were performed to assess muscle insulin sensitivity 
1 week after the final PMO injection and mice were euthanised and their tissues collected immediately afterwards.
Experiment 3: C57Bl/6 mice were fed an HFD or chow, as described for ‘Experiment 2’, and intravenously 
injected with 100 nmol PMO or saline once weekly for 5 weeks. One week after the final injection, IPITTs were 
performed to determine whole-body and muscle insulin sensitivity, and the mice were euthanised and their 
tissues harvested immediately afterwards.
RNA analysis. Frozen muscles were homogenised in Tri-reagent (Sigma-Aldrich) and RNA was extracted 
according to the manufacturer’s instructions. RNA was reverse transcribed using the qScript cDNA synthesis kit 
(Quanta Biosciences) or the Precision nanoScript2 Reverse Transcription kit (Primerdesign). Transcript levels 
were quantified in duplicate by real-time PCR using PerfeCta SYBR Green FastMix (Quanta Biosciences). Serial 
dilutions of a mixture of cDNA from all samples was prepared and targets amplified alongside the samples. The 
relative amounts of transcript were quantified using a standard curve constructed using the serial dilutions 
and normalised to Csnk2a2 mRNA, a reference gene which was selected using geNorm analysis (https ://genor 
m.cmgg.be/). Primer sequences are listed in Table 1.
Myostatin exon skipping was verified by nested RT-PCR amplification of an exon 1–exon 3 fragment using 
Quick-Load Taq master mix (New England Biolabs), followed by agarose gel separation of the PCR products, 
DNA extraction (QIAEX II kit; Qiagen) and sequencing of the PCR product (MWG Eurofins) corresponding 
to the skipped transcript. Full-length (exon 1–exon2 fragment: e1e2) and total myostatin transcript expression 
(exon 1 fragment: e1) was determined by real-time PCR, as described above. For intramuscular administration 
of PMO, exon skipping percentages for each mouse were calculated from the real-time PCR data as follows: % 
exon skipping = (∆e1 − ∆e1e2)/∆e1*100%, where ∆e1 = e1PMO/e1control*100% and ∆e1e2 = e1e2PMO/e1e2control*100%.
Statistics. Statistical analyses were carried out using SigmaPlot v12.3. Normality and equal variance of the 
data were tested with the Shapiro–Wilk test and Levene’s mean test, respectively. IPITT blood glucose data 
(Figs. 3c,d, 5c,d) and transcript levels (Figs. 3g,h and 4d), body mass (Fig. 5a,b), muscle mass (Fig. 4a,b) and 
muscle glucose uptake data (Fig. 4c) from HFD experiments were analysed by Two-Way Repeated Measures 
ANOVA. Myostatin transcript levels after i/v PMO administration (Fig.  6a,b) were analysed by Two-Way 
ANOVA. The Sidak-Holm method was used for post-hoc testing, following Two-Way ANOVAs. Tissue mass 
after i/v PMO administration (Figs. 5e–h) was analysed by One-Way ANOVA, after confirmation of normal 
distribution and equality of variance. If these assumptions were not met, a Kruskal–Wallis One-Way ANOVA 
was used. All data from experiments using intramuscular administration of PMO to chow-fed mice (Fig. 2a–d) 
were analysed by paired t-test (two-sided (Fig.  2a,b) or one-sided (Fig.  2c,d)), after confirmation of normal 
distribution and equality of variance. Body mass (Fig. 3a), fat pad mass (Fig. 3b) and %exon skipping (Fig. 3f) 
were analysed by unpaired t-test after confirmation of normal distribution and equality of variance. Statistical 
significance was accepted when p < 0.05.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
Table 1.  Sequences of primers used in RT-PCR.
Transcript Fw (5′—> 3′) Rv (5′—> 3′)
Mstn, e1 TGT TTA TAT TTA CCT GTT CAT GCT GAT GCC CCT CTT TTT CCA CAT TTTC 
Mstn, e1–e2 GAA GAT GAC GAT TAT CAC GCTAC CTT TTA CTA CTT TGT TGT ACT GTA TTT TAG 
Mstn, e1–e3 CAG TAC GAC GTC CAG AGG G GGC TTC AAA ATC GAC CGT GA
Mstn, e1–e3 nested GCA GTG ATG GCT CTT TGG AA GTC TCT CCG GGA CCT CTT G
Slc2a4 ACA CTG GTC CTA GCT GTA TTCT CCA GCC ACG TTG CAT TGT A
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